• BlossomHill Therapeutics partnered with Foundation Medicine to develop a companion diagnostic for BH-30643 in EGFR C797S-mutated non-small cell lung cancer.
• The collaboration will use the ongoing Phase 1/2 SOLARA trial of BH-30643 to validate the assay.
• The diagnostic will detect EGFR C797S, the most common EGFR mutation driving resistance to osimertinib treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220700PRIMZONEFULLFEED9850902) on October 22, 2026, and is solely responsible for the information contained therein.